Active Ingredient History
Arranon is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. It is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxicity. Administration of nelarabine in combination with adenosine deaminase inhibitors, such 195 as pentostatin, is not recommended. The most common (≥20%) adverse reactions were: anemia, thrombocytopenia, neutropenia, nausea, diarrhea, vomiting, constipation, fatigue, pyrexia, cough, and dyspnea NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (approved 2005)
Leukemia (Phase 3)
Leukemia, B-Cell (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, T-Cell (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 3)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 2)
Mucositis (Phase 3)
Multiple Myeloma (Phase 1)
Myelodysplastic Syndromes (Phase 1)
Myeloproliferative Disorders (Phase 1)
Sezary Syndrome (Phase 2)
Waldenstrom Macroglobulinemia (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
